Freezing plus chemotherapy and immunotherapy for lung cancer with airway blockage
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination treatment for lung cancer that is blocking the airway. It uses freezing (cryoablation) to shrink the tumor in the airway, along with chemotherapy and an immunotherapy drug (a treatment that helps your immune system fight cancer). The goal is to see if this approach is safe and effective for people who have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with non-small cell lung cancer (a common type of lung cancer) that has spread locally or to other parts of the body.
- You have not had any prior treatment (chemotherapy, radiation, etc.) for this cancer.
- You do not have certain genetic mutations (EGFR) that are treated with targeted pills.
- A tumor blocks at least one-third of your main airway (windpipe or large breathing tubes), causing symptoms like cough or trouble breathing.
- You are in generally good health (able to care for yourself) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab), chemotherapy, and a procedure called cryoablation (freezing the tumor) for people with a type of lung cancer called non-small cell lung cancer that has spread or come back. The goal is to see if this combination is safe and effective.
This trial tests a treatment for early-stage lung cancer (stage I-IIA) that uses extreme cold to freeze and destroy the tumor, called cryoablation. Some patients will also receive an immunotherapy drug called serplulimab, which helps the immune system fight the cancer, to see if adding it improves outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.